Published in the journal PlosOne.
This is the first study to provide evidence that obese people who suffer from Type 2 diabetes have more severe sleep apnea who were nondiabetic.
Research group on obesity and metabolism of lHospital Research Institute Universitari Vall dHebron has published the results of their study in the journal PlosOne, describing the differences between apnea syndrome (SAHS) among people with type 2 diabetes among obese individuals without type 2 diabetes. In this study involved the CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) and CIBER of Respiratory Diseases (CIBER) in addition to the Sleep Unit of Hospital Vall dHebron.
The results suggest that people with type 2 diabetes have more severe apnea. This finding should serve to devote special attention to people with obesity and Type 2 diabetes and assess corrective actions in these cases, because sleep apnea is clearly associated with an increased risk of hypertension, heart attacks and strokes . This study also opens up a whole series of hypotheses related to the fact that the respiratory center can be modulated in part by insulin receptors or the like.
What is the relationship between obesity, type 2 diabetes and the syndrome of sleep apnea?
SAHS (apnea and hypopnea syndrome sleep) is due to repeated obstruction or airway collapse suffered by some people while they sleep. This causes a reduction (hypopnea) or complete arrest (apnea) airflow to the lungs and can lead, among other effects, reduced oxygen levels and some small subconscients awakenings often, that they allow normal breathing until the next episode occurs. As a result, the main symptoms include excessive sleepiness during the day due to poor sleep quality, which can have many repercussions from the decline in intellectual capacity and performance, and traffic accidents. It also causes respiratory disorders, cardiovascular disorders including hypertension, arrhythmias, angina and myocardial infarction or stroke, and so on.
Obesity is the most important determinant for the occurrence of OSAHS. Approximately 50% of patients with a body mass index (BMI) greater than 30 kg / m² living with SAHS and 80% of patients with morbid obesity (BMI greater than 40 kg / m²). Recent years have increased the evidence suggests an association between SAHS and type 2 diabetes.
Current data suggest to us that the long-term exposure to hypoxia (decrease in the amount of oxygen we breathe) and apnea (short periods of time when breathing is interrupted) contributes to disorders of glucose metabolism. This is illustrated by the fact that among people with SAHS of a high prevalence of patients with high levels of glucose, insulin resistance and type 2 diabetes.
The first study provides evidence that obese people who suffer from Type 2 diabetes have more severe sleep apnea who were nondiabetic.
The study sought to define and realize this relationship and has really studied whether the same body mass index, waist circumference equal, the same characteristics in relation to snuff and age, people with type 2 diabetes SAHS suffered more than non-diabetics. The study results were surprising because it has found a high prevalence of SAHS in both groups but no differences (80% in diabetics and 78% in nondiabetics). The surprise was when they assessed the severity of apnea. We have detected that an equal number of apnea, people with diabetes have type 2 the most profound and severe. If we calculate the percentage of time a group and someone raises oxygen saturations below 90%, this is more than 3 times higher for the SAHS of diabetic patients, explains Dr. Rafael Simó, coordinator of this study. This saturation of oxygen (which measures the amount of oxygen into the blood) is the indicator of severity of apnea. These findings justified and is especially essential to make a study of sleep apnea obese people with type 2 diabetes, since it is clear that in these cases the SAHS exists and is more severe than in other patients. Implement corrective actions by the SAHS can prevent serious diseases with great impact as hypertension, myocardial infarction or stroke, concludes Dr. Simo.
Tuesday, September 1, 2009
16th Convocation of scholarships, awards and grants on food, nutrition and health of the Danone Institute.
The Danone Institute, scientific association nonprofit, which has among its objectives to encourage scientific research and education, rewards and supports for the sixteenth consecutive year of research, training and scientific dissemination on food, nutrition and health.
This initiative has so far favored the formation of 85 young researchers and 9 university graduates. In addition, 15 awards were granted to the Scientific Career of prestigious Spanish scientists and 15 prizes of Outreach - Journalistic.
So in 2009 are called:
5 Becas biannual totaling 30,000 each for scientific research on food, nutrition and health of university graduates in the fields of basic research, epidemiological, clinical and technological, in food, nutrition and health.
1 Prize of the Scientific Path Dr. Carles Martí Hennebergh endowed with 20,000 to Spanish scientists who work or have worked in Spain in the fields of clinical nutrition, metabolism, epidemiology, genetics, molecular biology and science and food technology.
1 Aid to 6,000 for projects developed by university graduates in health sciences, engineering or related technical fields related to food, nutrition and feeding.
1 Prize for popular science journalism on the theme Food, Nutrition and Health 3.000.
The deadline for applications is open until 31 May 2009. The bases and the applications are at the website of Danone Institute: www.institutodanone.es
In the case of scholarships, the selection of candidates is done on the report of the National Agency of Evaluation and Prospective (ANEP), and in the Scientific Career Award, the CVs of the candidates are evaluated by the University of Barcelona, matching the final decision in both cases, the Scientific Council of the Institute Danone.
This initiative has so far favored the formation of 85 young researchers and 9 university graduates. In addition, 15 awards were granted to the Scientific Career of prestigious Spanish scientists and 15 prizes of Outreach - Journalistic.
So in 2009 are called:
5 Becas biannual totaling 30,000 each for scientific research on food, nutrition and health of university graduates in the fields of basic research, epidemiological, clinical and technological, in food, nutrition and health.
1 Prize of the Scientific Path Dr. Carles Martí Hennebergh endowed with 20,000 to Spanish scientists who work or have worked in Spain in the fields of clinical nutrition, metabolism, epidemiology, genetics, molecular biology and science and food technology.
1 Aid to 6,000 for projects developed by university graduates in health sciences, engineering or related technical fields related to food, nutrition and feeding.
1 Prize for popular science journalism on the theme Food, Nutrition and Health 3.000.
The deadline for applications is open until 31 May 2009. The bases and the applications are at the website of Danone Institute: www.institutodanone.es
In the case of scholarships, the selection of candidates is done on the report of the National Agency of Evaluation and Prospective (ANEP), and in the Scientific Career Award, the CVs of the candidates are evaluated by the University of Barcelona, matching the final decision in both cases, the Scientific Council of the Institute Danone.
Manifesto of the SEC and FEC in support of AIDS prevention and sexually transmitted diseases.
The Spanish Society of Contraception (SEC) and the Spanish Foundation of Contraception (FEC) have issued a manifesto in defense of prevention of sexually transmitted infections / AIDS further to the recent statements by Pope Benedict XVI. The SEC is a scientific society of over five hundred doctors and nurses gynecologists. The SEC is headed by Dr. Esther de la Viuda and the FEC by Dr. Ezequiel Perez Campos. The manifesto is as follows:
Given recent statements by the highest Catholic hierarchy on the unsuitability concerning the dissemination of condoms to prevent AIDS and even counterproductive character, the SEC and the FEC, in its intention to maintain adequate information on issues affecting the sexual and reproductive health in the light of scientific evidence, are obliged to say:
1) Our respect to any ideological position in favor or against the use of contraceptives in general and condoms in particular, by those who share a particular religious doctrine and positioning.
2) Our total opposition to manipulation with statements that do not respond to scientific evidence to try these doctrines prevail, undermining them, to not be enhanced by a free choice of the people but mediated by telling the truth.
3) The claim undeniable Medical Science of the beneficial effect of condoms in controlling the spread of sexually transmitted infections in general and HIV / AIDS in particular. This clearly demonstrated and not up for discussion among the scientific community.
4) There are also scientific evidence that the approach of avoidance of STIs with a commitment to abstinence, shows data of this sort of pathology not less than the general population, so this type of intervention is not effective prevention measure.
5) The great importance of objective information for informed choice about whether people prefer condoms or abstinence to prevent STDs and AIDS. In the safety of religious conviction, fallacious arguments are not needed for monitoring.
With the intention of preserving the prevalence of scientific evidence and informed choice of people, consider it a priority to maintain the claims that science gives us about the effectiveness of condoms in preventing STIs and HIV / AIDS. Statements in another direction could worsen the problem, especially in places like sub-Saharan Africa with 22 million affected by HIV infection, a real tragedy for this entire population that requires decisive action in light of the scientific realities, without prejudice to religious ideologies indicate to his followers what is the way that supports their doctrine. Everyone is free to follow the path he wants, but it is unfair to manipulate scientific truth to get a human action that is appropriate to a particular conception of the world, life and relationships between people.
Given recent statements by the highest Catholic hierarchy on the unsuitability concerning the dissemination of condoms to prevent AIDS and even counterproductive character, the SEC and the FEC, in its intention to maintain adequate information on issues affecting the sexual and reproductive health in the light of scientific evidence, are obliged to say:
1) Our respect to any ideological position in favor or against the use of contraceptives in general and condoms in particular, by those who share a particular religious doctrine and positioning.
2) Our total opposition to manipulation with statements that do not respond to scientific evidence to try these doctrines prevail, undermining them, to not be enhanced by a free choice of the people but mediated by telling the truth.
3) The claim undeniable Medical Science of the beneficial effect of condoms in controlling the spread of sexually transmitted infections in general and HIV / AIDS in particular. This clearly demonstrated and not up for discussion among the scientific community.
4) There are also scientific evidence that the approach of avoidance of STIs with a commitment to abstinence, shows data of this sort of pathology not less than the general population, so this type of intervention is not effective prevention measure.
5) The great importance of objective information for informed choice about whether people prefer condoms or abstinence to prevent STDs and AIDS. In the safety of religious conviction, fallacious arguments are not needed for monitoring.
With the intention of preserving the prevalence of scientific evidence and informed choice of people, consider it a priority to maintain the claims that science gives us about the effectiveness of condoms in preventing STIs and HIV / AIDS. Statements in another direction could worsen the problem, especially in places like sub-Saharan Africa with 22 million affected by HIV infection, a real tragedy for this entire population that requires decisive action in light of the scientific realities, without prejudice to religious ideologies indicate to his followers what is the way that supports their doctrine. Everyone is free to follow the path he wants, but it is unfair to manipulate scientific truth to get a human action that is appropriate to a particular conception of the world, life and relationships between people.
Advancell investigating a drug for the treatment of palmar plantar very common in cancer patients.
The biotech company has signed an agreement with the company Nobera Pharma for the development of a new drug aimed at treating palmar plantar (hand-foot syndrome).
The palmar plantar is a common side effect in cancer patients treated with certain chemotherapies as capacetabina and other fluoropyrimidines. Following the initiation of chemotherapy a high percentage of patients develop a skin reaction where there is redness in the palms and soles of the feet, accompanied by other symptoms such as tingling, peeling and blistering.
Around 18,000 patients in Spain suffer from this side effect, affecting the quality of life and often have to reduce or even discontinue chemotherapy. There is currently no treatment for this indication, so that the development of this new medicine would solve a major problem in oncology.
Advancell, a leading biotechnology company cell research into methods for in vitro research and innovative therapeutic strategies to treat nanomedicine as unmet needs in health and wellness, has signed an agreement with the company Nobera Pharma SL development of a drug intended to treat an important side effect that occurs in cancer patients, the plantar palmar, also known as hand-foot syndrome.
The palmar plantar skin reaction to chemotherapy, relatively common, seen in erythema (redness) pain localized to the palms and soles. In general, is accompanied by paresthesias (tingling and numbness sensations) with appearance, as they aggravate the syndrome, peeling, blistering, ulceration and severe pain, leading to interfere with basic functions like walking or grasping objects. In more severe cases, is the main cause of dose reduction or discontinuation of chemotherapy.
Through this agreement, the Spanish biotechnology, located in the Barcelona Science Park and has research centers in Barcelona, Valencia and Santiago de Compostela, initiate the development of this drug, which was originally discovered and patented by Nobera Pharma SL, a company with a vocation to promote and develop innovations that originate in daily clinical oncology practice, in direct contact with patients.
There is currently no effective treatment for palmar plantar, whose mechanism of action is not clearly known. Treatment and prevention of this side effect would solve a major problem in oncology. It is especially common in patients treated with capacetabina and other fluoropyrimidines such as 5-fluorouracil, used to treat breast cancer and colorectal cancer and other cancers such as gastric or pancreatic. The incidence is about 50% of patients treated with capacetabina, ranging between 10 and 70% in patients treated with other fluoropyrimidines.
In Spain, about 18,000 patients suffer from this side effect. Specifically, about 40% of patients who develop plantar palmar forced to reduce the dose of treatment, and it is estimated that approximately 15% include breaking. Reduction or discontinuation of chemotherapy significantly reduces the chances of survival of these patients.
The drug's development is currently in preclinical phase and it is estimated that during the first quarter of 2010 was initiated clinical studies. The main objective of this development is that, with medication, patients can get to complete their planned chemotherapy as scheduled, in addition to substantially improving the quality of life of patients during treatment.
According to oncologists, the drug would solve a major problem for patients under said chemotherapy, for which there is today an effective solution.
About Advancell (www.advancell.net)
Advancell is a biotechnology company with proprietary technology and continuous innovation, is unmet needs in health and wellness products and efficient services and value added. The company draws on findings of the academic environment to improve, develop and exploit the market.
The company has three divisions: Advancell Therapeutics, which focuses on development to clinical proof of concept of innovative drugs by finding new applications for molecules already known Advancell Alternative Testing, that uses cell-based in vitro to predict the efficacy, safety and mechanism of action of molecules in development and Nanosystems Advancell, using nanomedicine, treat and prevent disease.
The business model Advancell you can significantly reduce costs, risks and time of drug development. Its projects in clinical stage nanomedicine focus on the treatment of psoriasis (in collaboration with ISDIN) and the development of a new orphan drug for Chronic Lymphocytic Leukemia (in collaboration with the British Protherics). Moreover, cellular reagents ready for use developed by Alternative Testing Advancell a position of European leadership in its class.
The company is located in the Barcelona Science Park and has research centers at the University of Santiago de Compostela and Hospital La Fe in Valencia.
The palmar plantar is a common side effect in cancer patients treated with certain chemotherapies as capacetabina and other fluoropyrimidines. Following the initiation of chemotherapy a high percentage of patients develop a skin reaction where there is redness in the palms and soles of the feet, accompanied by other symptoms such as tingling, peeling and blistering.
Around 18,000 patients in Spain suffer from this side effect, affecting the quality of life and often have to reduce or even discontinue chemotherapy. There is currently no treatment for this indication, so that the development of this new medicine would solve a major problem in oncology.
Advancell, a leading biotechnology company cell research into methods for in vitro research and innovative therapeutic strategies to treat nanomedicine as unmet needs in health and wellness, has signed an agreement with the company Nobera Pharma SL development of a drug intended to treat an important side effect that occurs in cancer patients, the plantar palmar, also known as hand-foot syndrome.
The palmar plantar skin reaction to chemotherapy, relatively common, seen in erythema (redness) pain localized to the palms and soles. In general, is accompanied by paresthesias (tingling and numbness sensations) with appearance, as they aggravate the syndrome, peeling, blistering, ulceration and severe pain, leading to interfere with basic functions like walking or grasping objects. In more severe cases, is the main cause of dose reduction or discontinuation of chemotherapy.
Through this agreement, the Spanish biotechnology, located in the Barcelona Science Park and has research centers in Barcelona, Valencia and Santiago de Compostela, initiate the development of this drug, which was originally discovered and patented by Nobera Pharma SL, a company with a vocation to promote and develop innovations that originate in daily clinical oncology practice, in direct contact with patients.
There is currently no effective treatment for palmar plantar, whose mechanism of action is not clearly known. Treatment and prevention of this side effect would solve a major problem in oncology. It is especially common in patients treated with capacetabina and other fluoropyrimidines such as 5-fluorouracil, used to treat breast cancer and colorectal cancer and other cancers such as gastric or pancreatic. The incidence is about 50% of patients treated with capacetabina, ranging between 10 and 70% in patients treated with other fluoropyrimidines.
In Spain, about 18,000 patients suffer from this side effect. Specifically, about 40% of patients who develop plantar palmar forced to reduce the dose of treatment, and it is estimated that approximately 15% include breaking. Reduction or discontinuation of chemotherapy significantly reduces the chances of survival of these patients.
The drug's development is currently in preclinical phase and it is estimated that during the first quarter of 2010 was initiated clinical studies. The main objective of this development is that, with medication, patients can get to complete their planned chemotherapy as scheduled, in addition to substantially improving the quality of life of patients during treatment.
According to oncologists, the drug would solve a major problem for patients under said chemotherapy, for which there is today an effective solution.
About Advancell (www.advancell.net)
Advancell is a biotechnology company with proprietary technology and continuous innovation, is unmet needs in health and wellness products and efficient services and value added. The company draws on findings of the academic environment to improve, develop and exploit the market.
The company has three divisions: Advancell Therapeutics, which focuses on development to clinical proof of concept of innovative drugs by finding new applications for molecules already known Advancell Alternative Testing, that uses cell-based in vitro to predict the efficacy, safety and mechanism of action of molecules in development and Nanosystems Advancell, using nanomedicine, treat and prevent disease.
The business model Advancell you can significantly reduce costs, risks and time of drug development. Its projects in clinical stage nanomedicine focus on the treatment of psoriasis (in collaboration with ISDIN) and the development of a new orphan drug for Chronic Lymphocytic Leukemia (in collaboration with the British Protherics). Moreover, cellular reagents ready for use developed by Alternative Testing Advancell a position of European leadership in its class.
The company is located in the Barcelona Science Park and has research centers at the University of Santiago de Compostela and Hospital La Fe in Valencia.
Brudy Technology is launching a product to treat problems of hyperactivity, attention deficit and behavioral disorders in children.
Spain has tripled in the diagnoses of children with attention deficit disorder with hyperactivity in the last four years
DHA developed by Brudy Technology is characterized by its reliability and high bioavailability
Brudy Kids is the first product of the new range Spanish pharmaceutical company is developing with the aim of providing new therapeutic tools to improve population health
The company's R & D Brudy Technology has just released Kids Brudy market, an antioxidant based on DHA, the only antioxidant that currently exist in the market and aimed at children. This product is particularly suitable for children with hyperactivity, attention deficit or conduct disorders.
Following the successful launch of Algatrium Plus, the company now launches Spanish Brudy Technology Farma line based on the same specific molecule of DHA (Omega 3) called Algatrium. This molecule, with a capacity up to 6 times higher than the other products in its class, is able to reduce oxidative damage to DNA. Research carried out by the company in some of the most prestigious Spanish universities have helped to develop an Omega 3, high bioavailability and high incorporation into cell membranes.
Brudy Kids comes at a time when the Ministry of Health data confirm an increase in cases of children with attention deficit disorder with hyperactivity (ADHD) in Spain. It is estimated that since 2005 they have tripled the number of hyperactive children. In Europe the same thing is happening in Holland, for example, one in three children are taking drugs for hyperactivity,
Compared with antioxidants commonly used in such treatments, Brudy Kids presents at all doses studied a greater effect and significantly reduces many of the symptoms associated with ADHD. In children with learning disabilities and ADHD are observed in reading and diction benefits and significant improvements in concentration, emotional stability and impulsivity, among other symptoms.
Brudy Kids comes in two forms (syrup and pearls) and can be found in pharmacies and drugstores. The new line of Pharma Brudy Technology is complemented by two products: Bruy Plus antioxidant treatments and slow aging and Derma Brudy to treat skin problems such as psoriasis or dermatitis
DHA developed by Brudy Technology is characterized by its reliability and high bioavailability
Brudy Kids is the first product of the new range Spanish pharmaceutical company is developing with the aim of providing new therapeutic tools to improve population health
The company's R & D Brudy Technology has just released Kids Brudy market, an antioxidant based on DHA, the only antioxidant that currently exist in the market and aimed at children. This product is particularly suitable for children with hyperactivity, attention deficit or conduct disorders.
Following the successful launch of Algatrium Plus, the company now launches Spanish Brudy Technology Farma line based on the same specific molecule of DHA (Omega 3) called Algatrium. This molecule, with a capacity up to 6 times higher than the other products in its class, is able to reduce oxidative damage to DNA. Research carried out by the company in some of the most prestigious Spanish universities have helped to develop an Omega 3, high bioavailability and high incorporation into cell membranes.
Brudy Kids comes at a time when the Ministry of Health data confirm an increase in cases of children with attention deficit disorder with hyperactivity (ADHD) in Spain. It is estimated that since 2005 they have tripled the number of hyperactive children. In Europe the same thing is happening in Holland, for example, one in three children are taking drugs for hyperactivity,
Compared with antioxidants commonly used in such treatments, Brudy Kids presents at all doses studied a greater effect and significantly reduces many of the symptoms associated with ADHD. In children with learning disabilities and ADHD are observed in reading and diction benefits and significant improvements in concentration, emotional stability and impulsivity, among other symptoms.
Brudy Kids comes in two forms (syrup and pearls) and can be found in pharmacies and drugstores. The new line of Pharma Brudy Technology is complemented by two products: Bruy Plus antioxidant treatments and slow aging and Derma Brudy to treat skin problems such as psoriasis or dermatitis
Sunday, February 15, 2009
The laser removes spider transdermal cellular tissue without damaging or leaving marks on the skin.
I update course in the techniques and endovenous laser therapy in chronic superficial venous insufficiency.
• Before your application, you will need the patient assessment by a vascular surgeon angiólogo or discard any venous complications.
• This is a timeless treat that can be applied at any time of year and the cosmetic results are seen after the first week.
Vascular spiders, and telangiectasias varículas people are recognized as a problem of aesthetic nature. However, as claims from the Spanish Chapter of Phlebology, "address before a reparative therapy is necessary for an assessment or a vascular surgeon who angiólogo discard any venous pathology associated with the appearance of them. Sometimes, "says Vicente Ibáñez," The emergence of a varícula can be a symptom of a deeper problem vein and its removal also removes the warning signal. "
Consider the chapter "Vascular spiders are a minimum of superficial chronic venous insufficiency. Does not require surgery and yes, if the patient so desires, aesthetic laser treatment or percutaneous sclerosis using microfoam. Both treatments are often not available within the national health system. "
Vascular spiders are small-caliber venous vessels is through the translucent skin. While its location is more frequent in the lower limbs, can also be seen in other areas, like in the face. Some have a red wine, others blue. Its most common location is the inside of the knee, the back legs and ankles. "
Conduct recommended to address these injuries to "the evaluation of a certified vascular surgeon, who seek the proper study of each case and then start treatment." At present there are different treatment methods, but today the percutaneous laser (exoláser) offers a real solution to the problem. "
The exoláser is an easily applicable method that does not damage tissues or structures, no signs and no depigmented skin. Being an application requires only painless, if persons of high sensitivity, an anesthetic ointment, speeding recovery. It is also a timeless treat that can be applied at any time of year and the cosmetic results are seen after the first week. "
Treatment with laser therapy requires "an indeterminate number of sessions, depending on the response of each patient. When varículas are associated with varicose veins, it is best to speak first on the varices, a sclerosis and finally the application of laser in transdermal varículas remaining. This process is producing better results and prevent its recurrence. "
• Before your application, you will need the patient assessment by a vascular surgeon angiólogo or discard any venous complications.
• This is a timeless treat that can be applied at any time of year and the cosmetic results are seen after the first week.
Vascular spiders, and telangiectasias varículas people are recognized as a problem of aesthetic nature. However, as claims from the Spanish Chapter of Phlebology, "address before a reparative therapy is necessary for an assessment or a vascular surgeon who angiólogo discard any venous pathology associated with the appearance of them. Sometimes, "says Vicente Ibáñez," The emergence of a varícula can be a symptom of a deeper problem vein and its removal also removes the warning signal. "
Consider the chapter "Vascular spiders are a minimum of superficial chronic venous insufficiency. Does not require surgery and yes, if the patient so desires, aesthetic laser treatment or percutaneous sclerosis using microfoam. Both treatments are often not available within the national health system. "
Vascular spiders are small-caliber venous vessels is through the translucent skin. While its location is more frequent in the lower limbs, can also be seen in other areas, like in the face. Some have a red wine, others blue. Its most common location is the inside of the knee, the back legs and ankles. "
Conduct recommended to address these injuries to "the evaluation of a certified vascular surgeon, who seek the proper study of each case and then start treatment." At present there are different treatment methods, but today the percutaneous laser (exoláser) offers a real solution to the problem. "
The exoláser is an easily applicable method that does not damage tissues or structures, no signs and no depigmented skin. Being an application requires only painless, if persons of high sensitivity, an anesthetic ointment, speeding recovery. It is also a timeless treat that can be applied at any time of year and the cosmetic results are seen after the first week. "
Treatment with laser therapy requires "an indeterminate number of sessions, depending on the response of each patient. When varículas are associated with varicose veins, it is best to speak first on the varices, a sclerosis and finally the application of laser in transdermal varículas remaining. This process is producing better results and prevent its recurrence. "
The present and the future of drug treatment of hypertension through fixed combinations.
- "As it has extended the combined therapy, have greatly increased rates of control, because it manages to operate in different systems involved and broadened the spectrum of effectiveness," says Dr. Antonio Coca, coordinator of the Scientific Committee of the Course Cardiovascular Medicine 2009.
- Also fixed combinations are beneficial, they get a 24 percent lower risk of default by the patient, which today is around 50 percent.
- Dr. Bernard Waeber, chief of the Division of Clinical Pathophysiology University Hospital of Lausanne, who at the satellite symposium prior to the course has provided the scientific basis of the association between olmesartán (ARB) and amlodipine (calcium antagonist), has suggested that this association is indicated in any patient with essential hypertension.
"To date, compliance with the proper lifestyle to prevent and treat hypertension (HTA) has been a failure, we have failed to stimulate the patients. On the other hand, the doctor has now drugs to treat it, and although none has proved itself a panacea, combined provide multiple opportunities and effective. " This was revealed Dr. Antonio Coca, head of the Hypertension Unit of the Hospital Clínic of Barcelona and coordinator of the Scientific Committee of the Course of Cardiovascular Medicine 2009, organized by scientific area Menarini. According to doctors gathered at the meeting, nearly 300, the present and the future of drug treatment of hypertension through the combination of antihypertensive treatment in a single tablet. "As has been extended combination therapy, have greatly increased rates of control, because it manages to operate in different systems involved and broadened the spectrum of effectiveness," said Dr. Coca. "It also adds beneficial combinations are also fixed, getting a 24 percent lower risk of default by the patient, which today is around 50 percent."
Control of hypertension
Dr Josep Redon, coordinator of the Hypertension Unit, Hospital Clínico Universitario de Valencia, recalled that hypertension is the leading cause of death worldwide and there is still a 50 per cent of people who do not have their numbers controlled blood pressure . "The reasons are that the patient, tired of taking multiple tablets, just not meeting the treatment, also a record low of doctors and finally, the structure of the health system, which sometimes hinders the optimal treatment of these patients" . Redón The doctor has stated that although there are combinations that contribute nothing, as ACE inhibitors and ARBs, they combined with calcium antagonists and diuretics, have demonstrated improvement in compliance and resistance in the long term. His paper concluded: "If the doctor has the right combination for each patient, you can reach very high levels of control that may be around twice the current."
Olmesartán + amlodipine
Dr. Bernard Waeber, chief of the Division of Clinical Pathophysiology University Hospital of Lausanne, who at the satellite symposium prior to the course has provided the scientific basis of the association between olmesartán (ARB) and amlodipine (calcium antagonist), has been suggested that this association is indicated in any patient with essential hypertension. "The effect of antihypertensive olmesartán appears in the first two weeks after starting treatment. This rapid onset of action provides additional benefits as it helps to improve compliance, "he remarked Waeber. Spain Menarini Group will market, from the year 2009, this new partnership in Spain.
Course Objectives
The Course of Cardiovascular Medicine, which took place between Monday and Tuesday in Barcelona, aims to provide relevant training to a group of doctors with more difficulties in accessing training, such as specialists in the Spanish second-level hospitals. During the two days that has lasted the course, has addressed the heart failure, diabetes, antiagregación, the blockade of the renin-angiotensin system and the treatment of hypertensive multifactorial systematic risk.
This is one of the most important training activities organized by scientific area Menarini, the Menarini pharmaceutical entity engaged in health education. Each year, Area Science Menarini organizes more than 1,700 training activities on health in Spain.
- Also fixed combinations are beneficial, they get a 24 percent lower risk of default by the patient, which today is around 50 percent.
- Dr. Bernard Waeber, chief of the Division of Clinical Pathophysiology University Hospital of Lausanne, who at the satellite symposium prior to the course has provided the scientific basis of the association between olmesartán (ARB) and amlodipine (calcium antagonist), has suggested that this association is indicated in any patient with essential hypertension.
"To date, compliance with the proper lifestyle to prevent and treat hypertension (HTA) has been a failure, we have failed to stimulate the patients. On the other hand, the doctor has now drugs to treat it, and although none has proved itself a panacea, combined provide multiple opportunities and effective. " This was revealed Dr. Antonio Coca, head of the Hypertension Unit of the Hospital Clínic of Barcelona and coordinator of the Scientific Committee of the Course of Cardiovascular Medicine 2009, organized by scientific area Menarini. According to doctors gathered at the meeting, nearly 300, the present and the future of drug treatment of hypertension through the combination of antihypertensive treatment in a single tablet. "As has been extended combination therapy, have greatly increased rates of control, because it manages to operate in different systems involved and broadened the spectrum of effectiveness," said Dr. Coca. "It also adds beneficial combinations are also fixed, getting a 24 percent lower risk of default by the patient, which today is around 50 percent."
Control of hypertension
Dr Josep Redon, coordinator of the Hypertension Unit, Hospital Clínico Universitario de Valencia, recalled that hypertension is the leading cause of death worldwide and there is still a 50 per cent of people who do not have their numbers controlled blood pressure . "The reasons are that the patient, tired of taking multiple tablets, just not meeting the treatment, also a record low of doctors and finally, the structure of the health system, which sometimes hinders the optimal treatment of these patients" . Redón The doctor has stated that although there are combinations that contribute nothing, as ACE inhibitors and ARBs, they combined with calcium antagonists and diuretics, have demonstrated improvement in compliance and resistance in the long term. His paper concluded: "If the doctor has the right combination for each patient, you can reach very high levels of control that may be around twice the current."
Olmesartán + amlodipine
Dr. Bernard Waeber, chief of the Division of Clinical Pathophysiology University Hospital of Lausanne, who at the satellite symposium prior to the course has provided the scientific basis of the association between olmesartán (ARB) and amlodipine (calcium antagonist), has been suggested that this association is indicated in any patient with essential hypertension. "The effect of antihypertensive olmesartán appears in the first two weeks after starting treatment. This rapid onset of action provides additional benefits as it helps to improve compliance, "he remarked Waeber. Spain Menarini Group will market, from the year 2009, this new partnership in Spain.
Course Objectives
The Course of Cardiovascular Medicine, which took place between Monday and Tuesday in Barcelona, aims to provide relevant training to a group of doctors with more difficulties in accessing training, such as specialists in the Spanish second-level hospitals. During the two days that has lasted the course, has addressed the heart failure, diabetes, antiagregación, the blockade of the renin-angiotensin system and the treatment of hypertensive multifactorial systematic risk.
This is one of the most important training activities organized by scientific area Menarini, the Menarini pharmaceutical entity engaged in health education. Each year, Area Science Menarini organizes more than 1,700 training activities on health in Spain.
Subscribe to:
Posts (Atom)
